
Merck chief executive Karl-Ludwig Kley to step down in April
pharmafile | March 9, 2016 | Appointment | Medical Communications, Research and Development |Â Â Denreon, Karl-Ludwig Kley, Merck, karl ludwig kleyÂ
It has been announced that Karl-Ludwig Kley, chief executive officer at Merck, will step down from his position at the end of April to join German energy company, EON.
Kley has been at the helm of the German pharma company for almost nine years. While he hasn’t overseen any new medicines launched during that time, Kley has made significant efforts to diversify Merck’s offering in this time period, including last year’s acquisition of Sigma Alridch which was the largest in Merck’s history. This acquisition led to a rise in Q4 profits, which were announced just yesterday (Tuesday 8th March).
Kley previously held positions as chief financial officer at airline Lufthansa as well as executive roles with Bayer. His new role will see him replace Werner Wenning as chairman of the supervisory board of EON, and will take the position after the company’s annual general meeting on June 8.
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






